Metabotropic glutamate receptor structures reveal potential drug target for neurological diseases

Metabotropic glutamate receptor structures uncover mechanisms of class C GPCR dimerization and activation
Structures of mGlu2 in different conformational states. Credit: Dr. WU Beili’s laboratory

Metabotropic glutamate receptors (mGlus), which belong to class C G-protein-coupled receptor (GPCR) family, play key roles in modulating neuronal excitability and synaptic transmission in the central nervous system. The mGlus (mGlu1-8) identified in humans serve as therapeutic targets for a variety of neurological and psychiatric disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia, but drugs targeting the mGlus are not currently available.

In two back-to-back studies published in Nature, a team of researchers led by Wu Beili, Zhao Qiang, Wang Mingwei and Liu Hong at the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences (CAS), collaborating with research groups led by Sun Fei at Institute of Biophysics of CAS and by Liu Jianfeng from Huazhong University of Science and Technology, respectively, determined six (cryo-EM) structures of several mGlus in distinct functional and dimeric states, which offers opportunities to develop new treatment for neurological and psychiatric diseases.

The researchers solved the structures of mGlu2 and mGlu7 homodimers in the inactive state; the structures revealed distinct dimerization modes. Using mutagenesis and cell signaling assays, the researchers found that the (TMD) dimer interface in the inactive mGlu2 homodimer is subtype-specific and has a critical role in stabilizing the inactive conformation of the receptor. They determined the structures of mGlu2 homodimer in the inactive, intermediate activation (Gi protein-free) and fully activate (Gi protein-bound) states.

The structure of mGlu4 in complex with the Gi protein reveals a similar dimeric association mode, suggesting that different mGlus may modulate receptor activation in a similar manner.

Additionally, the researchers found that extracellular domains (ECDs) of both subunits are occupied by the agonist, but only one TMD is capable of coupling to G protein. The asymmetric dimer association provides different interaction environments for the two subunits and may cause distinct conformational changes within the two TMDs, which only allow one subunit to recognize the G protein. The G protein then forms a spatial hindrance to block the G protein coupling by the other subunit.

The studies offer the first thorough view of receptor conformational changes during the process of mGlu activation and give valuable insights into asymmetric activation of mGlus. They highlight the importance of cooperativity between different subunits as well as between different receptor domains in controlling receptor function, thereby expanding the knowledge about signal transduction of class C GPCRs.


Explore further

Glucagon receptor structures reveal G protein specificity mechanism

More information: Shuling Lin et al, Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4, Nature (2021). DOI: 10.1038/s41586-021-03495-2

Juan Du et al, Structures of human mGlu2 and mGlu7 homo- and heterodimers, Nature (2021). DOI: 10.1038/s41586-021-03641-w

Journal information: Nature

Citation: Metabotropic glutamate receptor structures reveal potential drug target for neurological diseases (2021, June 17) retrieved 24 July 2021 from https://phys.org/news/2021-06-metabotropic-glutamate-receptor-reveal-potential.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
12 shares

Feedback to editors

User comments